Agreement with Rosemont Pharmaceuticals provides for all-cash consideration of $2.70 per share
Tender offer price represents 41.1% premium to 30-day volume-weighted average price and 51.7% premium to the closing price on November 13, 2026
Tender offer support agreements secured from Nantahala Capital Management, Stonepine Capital Management and Aytu's directors and officers
Closing is anticipated to occur by the end of calendar year 2026, subject to the satisfaction or waiver of the conditions to the tender offer
DENVER, CO / ACCESS Newswire / November 16, 2026 / Aytu BioPharma, Inc. (the "Company" or "Aytu") (NASDAQ:AYTU), a pharmaceutical company focused on advancing innovative medicines for complex central nervous system diseases to improve the quality of life for patients, today announced that it has entered into a definitive merger agreement with Rosemont Pharmaceuticals Holdings, Inc. ("Rosemont"), pursuant to which Rosemont would acquire Aytu, through a tender offer for $2.70 per share.
Under the terms of the merger agreement, a wholly-owned subsidiary of Rosemont will commence a tender offer to acquire all outstanding shares of Aytu common stock. The transaction is structured as a tender offer to be followed by a merger, subject to customary conditions to the tender offer and merger, including the tender of shares representing at least a majority of the total number of outstanding shares of Aytu common stock and the exercise or termination of certain outstanding warrants. Following the successful completion of the tender offer, Rosemont will acquire all remaining shares not tendered in the tender offer (other than shares for which appraisal rights are properly exercised) through a second-step merger at the same price paid in the tender offer.
Rosemont intends to commence the tender offer and file a Schedule TO within 10 business days, and Aytu will file a Schedule 14D-9 with respect to the tender offer substantially concurrently with the commencement of the tender offer, each of which will include additional details on the transaction and process undertaken by the Company.
The transaction was unanimously approved by the Aytu board of directors and closing is anticipated to occur in late December 2026, subject to the satisfaction or waiver of the conditions to the tender offer. Aytu's executive officers, directors and certain stockholders affiliated with Nantahala Capital Management and Stonepine Capital Management, have signed tender and support agreements under which such stockholders agreed, among other things, to tender their shares in the tender offer and to the termination or exercise of any warrants held by them prior to the Effective Time, in exchange for the consideration payable in connection with the transaction in accordance with the terms of such warrants.